BRWM
PLX icon

B. Riley Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

B. Riley Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,833
Closed -$8K – 426
2019
Q1 		$8K Hold
1,833
– – ﹤0.01% 397
2018
Q4 		$6K Hold
1,833
– – ﹤0.01% 344
2018
Q3 		$13K Buy
+1,833
New +$9.2K ﹤0.01% 325

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

B. Riley Wealth Management's PLX Position: Q2 2019 in Review

B. Riley Wealth Management sold out of Protalix BioTherapeutics (PLX) in Q2 2019, closing a stake of 1,833 shares — an estimated $8K sold.

B. Riley Wealth Management first reported a position in PLX in Q3 2018 and held it in 3 quarters. The position peaked at $13K in Q3 2018. 31 funds tracked by Wall St. Rank hold PLX as of Q2 2019.

  • B. Riley Wealth Management reported no remaining Protalix BioTherapeutics position as of Q2 2019 after selling out during the quarter.
  • B. Riley Wealth Management sold 1,833 Protalix BioTherapeutics shares in Q2 2019, an estimated $8K.
  • B. Riley Wealth Management first reported a position in Protalix BioTherapeutics in Q3 2018 and held it in 3 quarters.
  • B. Riley Wealth Management's Protalix BioTherapeutics position peaked at $13K in Q3 2018.
  • 31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2019.

Based on B. Riley Wealth Management's 13F filing for Q2 2019, filed 14 Aug 2019.